NCT04012606View on ClinicalTrials.gov

Toripalimab in Combination With Platinum Plus Etoposidein Patients With Extensive-Stage Small Cell Lung Cancer

PHASE3CompletedINTERVENTIONAL

Enrollment

442

Participants

Timeline

Start Date

July 23, 2019

Primary Completion Date

April 20, 2023

Study Completion Date

April 20, 2023

Conditions

Small Cell Lung Cancer

Interventions

DRUG

TORIPALIMAB INJECTION(JS001 ) Carboplatin Cisplatin Etoposide Placebo

TORIPALIMAB INJECTION(JS001 ) or Placebo combined with chemotherapy, 240mg/6ml/vial, Q3W,up to 2 years of treatment.

Trial Locations (1)

Unknown

Ying Cheng, Changchun

All Listed Sponsors

lead

Shanghai Junshi Bioscience Co., Ltd.

OTHER

NCT04012606 - Toripalimab in Combination With Platinum Plus Etoposidein Patients With Extensive-Stage Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter